184 related articles for article (PubMed ID: 34535560)
1. Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair.
Dow J; Krysztofiak A; Liu Y; Colon-Rios DA; Rogers FA; Glazer PM
Mol Cancer Res; 2021 Dec; 19(12):2057-2067. PubMed ID: 34535560
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity.
Smith S; Fox J; Mejia M; Ruangpradit W; Saberi A; Kim S; Choi Y; Oh S; Wang Y; Choi K; Li L; Hendrickson EA; Takeda S; Muller M; Myung K
PLoS One; 2014; 9(1):e87203. PubMed ID: 24466340
[TBL] [Abstract][Full Text] [Related]
3. HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma.
Garrett MC; Albano R; Carnwath T; Elahi L; Behrmann CA; Pemberton M; Woo D; O'Brien E; VanCauwenbergh B; Perentesis J; Shah S; Hagan M; Kendler A; Zhao C; Paranjpe A; Roskin K; Kornblum H; Plas DR; Lu QR
Sci Rep; 2023 Aug; 13(1):12433. PubMed ID: 37528157
[TBL] [Abstract][Full Text] [Related]
4. Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat.
Chang CM; Ramesh KK; Huang V; Gurbani S; Kleinberg LR; Weinberg BD; Shim H; Shu HG
Tomography; 2023 May; 9(3):942-954. PubMed ID: 37218937
[TBL] [Abstract][Full Text] [Related]
5. IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.
Sears TK; Horbinski CM; Woolard KD
J Neurooncol; 2021 Sep; 154(2):159-170. PubMed ID: 34424450
[TBL] [Abstract][Full Text] [Related]
6. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
Sulkowski PL; Corso CD; Robinson ND; Scanlon SE; Purshouse KR; Bai H; Liu Y; Sundaram RK; Hegan DC; Fons NR; Breuer GA; Song Y; Mishra-Gorur K; De Feyter HM; de Graaf RA; Surovtseva YV; Kachman M; Halene S; Günel M; Glazer PM; Bindra RS
Sci Transl Med; 2017 Feb; 9(375):. PubMed ID: 28148839
[TBL] [Abstract][Full Text] [Related]
7. IDH1
Kim GH; Choi SY; Oh TI; Kan SY; Kang H; Lee S; Oh T; Ko HM; Lim JH
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151327
[TBL] [Abstract][Full Text] [Related]
8. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
9. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
[TBL] [Abstract][Full Text] [Related]
10. EZH2 Inhibition Sensitizes IDH1R132H-Mutant Gliomas to Histone Deacetylase Inhibitor.
Sprinzen L; Garcia F; Mela A; Lei L; Upadhyayula P; Mahajan A; Humala N; Manier L; Caprioli R; Quiñones-Hinojosa A; Casaccia P; Canoll P
Cells; 2024 Jan; 13(3):. PubMed ID: 38334611
[TBL] [Abstract][Full Text] [Related]
11. Loss of FBXW7 Correlates with Increased IDH1 Expression in Glioma and Enhances IDH1-Mutant Cancer Cell Sensitivity to Radiation.
Yang Z; Hu N; Wang W; Hu W; Zhou S; Shi J; Li M; Jing Z; Chen C; Zhang X; Yang R; Fu X; Wang X
Cancer Res; 2022 Feb; 82(3):497-509. PubMed ID: 34737211
[TBL] [Abstract][Full Text] [Related]
12. Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.
Ohba S; Mukherjee J; See WL; Pieper RO
Cancer Res; 2014 Sep; 74(17):4836-44. PubMed ID: 25035396
[TBL] [Abstract][Full Text] [Related]
13. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.
Borodovsky A; Salmasi V; Turcan S; Fabius AW; Baia GS; Eberhart CG; Weingart JD; Gallia GL; Baylin SB; Chan TA; Riggins GJ
Oncotarget; 2013 Oct; 4(10):1737-47. PubMed ID: 24077805
[TBL] [Abstract][Full Text] [Related]
14. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
[TBL] [Abstract][Full Text] [Related]
15. An in vivo patient-derived model of endogenous IDH1-mutant glioma.
Luchman HA; Stechishin OD; Dang NH; Blough MD; Chesnelong C; Kelly JJ; Nguyen SA; Chan JA; Weljie AM; Cairncross JG; Weiss S
Neuro Oncol; 2012 Feb; 14(2):184-91. PubMed ID: 22166263
[TBL] [Abstract][Full Text] [Related]
16. Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration.
Cao H; Zhu G; Sun L; Chen G; Ma X; Luo X; Zhu J
Eur J Med Chem; 2019 Dec; 183():111694. PubMed ID: 31561044
[TBL] [Abstract][Full Text] [Related]
17. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.
Bunse L; Pusch S; Bunse T; Sahm F; Sanghvi K; Friedrich M; Alansary D; Sonner JK; Green E; Deumelandt K; Kilian M; Neftel C; Uhlig S; Kessler T; von Landenberg A; Berghoff AS; Marsh K; Steadman M; Zhu D; Nicolay B; Wiestler B; Breckwoldt MO; Al-Ali R; Karcher-Bausch S; Bozza M; Oezen I; Kramer M; Meyer J; Habel A; Eisel J; Poschet G; Weller M; Preusser M; Nadji-Ohl M; Thon N; Burger MC; Harter PN; Ratliff M; Harbottle R; Benner A; Schrimpf D; Okun J; Herold-Mende C; Turcan S; Kaulfuss S; Hess-Stumpp H; Bieback K; Cahill DP; Plate KH; Hänggi D; Dorsch M; Suvà ML; Niemeyer BA; von Deimling A; Wick W; Platten M
Nat Med; 2018 Aug; 24(8):1192-1203. PubMed ID: 29988124
[TBL] [Abstract][Full Text] [Related]
18. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
19. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
[TBL] [Abstract][Full Text] [Related]
20. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
Yamashita AS; da Costa Rosa M; Borodovsky A; Festuccia WT; Chan T; Riggins GJ
Neuro Oncol; 2019 Feb; 21(2):189-200. PubMed ID: 30184215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
